EVA Pharma Deepens Its Roots in China’s Thriving Biopharmaceutical Ecosystem with The Inauguration of Its Hangzhou Office
Hangzhou, Cairo, 26 June 2025 –  EVA Pharma, one of the leading pharmaceutical companies driving healthcare innovation and access across the Middle East and Africa, has signed a cooperation agreement with the Chaming Qiantang Management Office in Hangzhou, strengthening its strategic global expansions and commitment to innovation, localization, and global collaboration in China.

EVA Pharma’s eighth global office, located in the vibrant city of Hangzhou, was established following the signing of the agreement. Under this cooperation, EVA Pharma will leverage the advantageous resources of Qiantang District’s biopharmaceutical industry. The new branch will focus on research and development and strategic supply operations in the field of pharmaceuticals, vaccines, and biologics.

“By anchoring our presence in leading innovation hubs like Hangzhou’s Biopharma Town, EVA Pharma is shaping a future where collaboration drives resilience.” said Riad Armanious, CEO of EVA Pharma. “In Qiantang District, we bring our experience in localizing production and advancing innovation to build a network that makes access to high-quality healthcare faster, smarter, and more equitable, from China to the Middle East and beyond.”

With significant national investment, China innovation ecosystem has made it a global leader in Cell and Gene Therapy (CGT) and Hangzhou is at the forefront. Home to cutting-edge academic centers, world-class incubators, and specialized GMP platforms, BioPharma Town has attracted a growing number of companies focused on mRNA vaccines, CAR-T therapy, gene editing, and regenerative medicine.

 Through this partnership, EVA Pharma aims to leverage local capabilities in Hangzhou BioPharma Town while contributing its own R&D expertise, analytical development workflows, and regional regulatory knowledge to explore joint projects in vaccine technology, mRNA applications, and therapeutic biologics.

End of Press Release